First-in-class small molecule mGlu2 inhibitor as a treatment for mild neurocogmitive disorder (COGNI+)
Lead Participant:
PHARMIDEX PHARMACEUTICAL SERVICES LIMITED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| PHARMIDEX PHARMACEUTICAL SERVICES LIMITED | £519,655 | £ 309,741 |
Participant |
||
| UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION | ||
| INNOVATE UK |
People |
ORCID iD |
| Mo Alavijeh (Project Manager) |